Publication:
Cardiometabolic Therapy and Mortality in Very Old Patients With Diabetes Hospitalized due to COVID-19.

dc.contributor.authorRamos-Rincon, Jose Manuel
dc.contributor.authorPerez-Belmonte, Luis M
dc.contributor.authorCarrasco-Sanchez, Francisco Javier
dc.contributor.authorJansen-Chaparro, Sergio
dc.contributor.authorDe-Sousa-Baena, Mercedes
dc.contributor.authorBueno-Fonseca, Jose
dc.contributor.authorPerez-Aguilar, Maria
dc.contributor.authorArevalo-Cañas, Coral
dc.contributor.authorBacete-Cebrian, Marta
dc.contributor.authorMendez-Bailon, Manuel
dc.contributor.authorFiteni-Mera, Isabel
dc.contributor.authorGonzalez-Garcia, Andres
dc.contributor.authorNavarro-Romero, Francisco
dc.contributor.authorTuñon-de-Almeida, Carlota
dc.contributor.authorMuñiz-Nicolas, Gemma
dc.contributor.authorGonzalez-Noya, Amara
dc.contributor.authorHernandez-Milian, Almudena
dc.contributor.authorGarcia-Garcia, Gema Maria
dc.contributor.authorAlcala-Pedrajas, Jose Nicolas
dc.contributor.authorHerrero-Garcia, Virginia
dc.contributor.authorCorral-Gudino, Luis
dc.contributor.authorComas Casanova, Pere
dc.contributor.authorMeijide-Miguez, Hector
dc.contributor.authorCasas-Rojo, Jose Manuel
dc.contributor.authorGomez-Huelgas, Ricardo
dc.contributor.groupSEMI-COVID-19 Network
dc.date.accessioned2023-02-09T11:38:24Z
dc.date.available2023-02-09T11:38:24Z
dc.date.issued2021-05-04
dc.description.abstractThe effects of cardiometabolic drugs on the prognosis of diabetic patients with COVID-19, especially very old patients, are not well known. This work was aimed to analyze the association between preadmission cardiometabolic therapy (antidiabetic, antiaggregant, antihypertensive, and lipid-lowering drugs) and in-hospital mortality among patients ≥80 years with type 2 diabetes mellitus (T2DM) hospitalized for COVID-19. We conducted a nationwide, multicenter, observational study in patients ≥80 years with T2DM hospitalized for COVID-19 between March 1 and May 29, 2020. The primary outcome measure was in-hospital mortality. A multivariate logistic regression analysis was performed to assess the association between preadmission cardiometabolic therapy and in-hospital mortality. Of the 2 763 patients ≥80 years old hospitalized due to COVID-19, 790 (28.6%) had T2DM. Of these patients, 385 (48.7%) died during admission. On the multivariate analysis, the use of dipeptidyl peptidase-4 inhibitors (adjusted odds ratio [AOR] 0.502, 95% confidence interval [CI]: 0.309-0.815, p = .005) and angiotensin receptor blockers (AOR 0.454, 95% CI: 0.274-0.759, p = .003) were independent protectors against in-hospital mortality, whereas the use of acetylsalicylic acid was associated with higher in-hospital mortality (AOR 1.761, 95% CI: 1.092-2.842, p = .020). Other antidiabetic drugs, angiotensin-converting enzyme inhibitors, and statins showed neutral association with in-hospital mortality. We found important differences between cardiometabolic drugs and in-hospital mortality in older patients with T2DM hospitalized for COVID-19. Preadmission treatment with dipeptidyl peptidase-4 inhibitors and angiotensin receptor blockers could reduce in-hospital mortality; other antidiabetic drugs, angiotensin-converting enzyme inhibitors, and statins seem to have a neutral effect; and acetylsalicylic acid could be associated with excess mortality.
dc.description.versionSi
dc.identifier.citationRamos-Rincón JM, Pérez-Belmonte LM, Carrasco-Sánchez FJ, Jansen-Chaparro S, De-Sousa-Baena M, Bueno-Fonseca J, et al. Cardiometabolic Therapy and Mortality in Very Old Patients With Diabetes Hospitalized due to COVID-19. J Gerontol A Biol Sci Med Sci. 2021 Jul 13;76(8):e102-e109
dc.identifier.doi10.1093/gerona/glab124
dc.identifier.essn1758-535X
dc.identifier.pmcPMC8135901
dc.identifier.pmid33945610
dc.identifier.pubmedURLhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8135901/pdf
dc.identifier.unpaywallURLhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8135901
dc.identifier.urihttp://hdl.handle.net/10668/17741
dc.issue.number8
dc.journal.titleThe journals of gerontology. Series A, Biological sciences and medical sciences
dc.journal.titleabbreviationJ Gerontol A Biol Sci Med Sci
dc.language.isoen
dc.organizationÁrea Sanitaria Norte de Córdoba
dc.organizationHospital Universitario Juan Ramón Jiménez
dc.organizationHospital Costa del Sol
dc.organizationHospital Universitario Regional de Málaga
dc.organizationInstituto de Investigación Biomédica de Málaga-IBIMA
dc.organizationAGS - Norte de Córdoba
dc.page.number8
dc.provenanceRealizada la curación de contenido 14/03/2025
dc.publisherOxford University Press
dc.pubmedtypeJournal Article
dc.pubmedtypeMulticenter Study
dc.pubmedtypeObservational Study
dc.relation.publisherversionhttps://academic.oup.com/biomedgerontology/article-lookup/doi/10.1093/gerona/glab124
dc.rights.accessRightsRestricted Access
dc.subjectAge ≥ 80
dc.subjectCardiometabolic therapy
dc.subjectCoronavirus disease-2019
dc.subjectMortality
dc.subjectType 2 diabetes
dc.subjectÁrea Sanitaria Norte de Córdoba
dc.subject.decsMortalidad Hospitalaria
dc.subject.decsHipoglucemiantes
dc.subject.decsAspirina
dc.subject.decsInhibidores de la Enzima Convertidora de Angiotensina
dc.subject.decsInhibidores de Hidroximetilglutaril-CoA Reductasas
dc.subject.decsAntagonistas de Receptores de Angiotensina
dc.subject.meshAged, 80 and over
dc.subject.meshAngiotensin Receptor Antagonists
dc.subject.meshCOVID-19
dc.subject.meshCardiovascular Diseases
dc.subject.meshDiabetes Mellitus, Type 2
dc.subject.meshDipeptidyl-Peptidase IV Inhibitors
dc.subject.meshFemale
dc.subject.meshHospital Mortality
dc.subject.meshHospitalization
dc.subject.meshHumans
dc.subject.meshHypoglycemic Agents
dc.subject.meshMale
dc.subject.meshSARS-CoV-2
dc.titleCardiometabolic Therapy and Mortality in Very Old Patients With Diabetes Hospitalized due to COVID-19.
dc.typeresearch article
dc.type.hasVersionVoR
dc.volume.number76
dspace.entity.typePublication

Files

Original bundle

Now showing 1 - 1 of 1
No Thumbnail Available
Name:
RISalud_Accesorestringido.pdf
Size:
93.39 KB
Format:
Adobe Portable Document Format